Roche at CTAD 2018
11th Clinical Trials on Alzheimer's Disease
Oct 24, 2018 | Alzheimer's DiseaseOct 24, 2018 | Alzheimer's Disease
The GRADUATE program includes two identical randomized, multicenter, double-blind, placebo-controlled Phase III studies (GRADUATE I, NCT03444870; GRADUATE II, NCT03443973) designed to evaluate the efficacy and safety of subcutaneous gantenerumab versus placebo in patients with early (prodromal-to-mild) AD. Here we present a detailed overview of the design of these studies.
Oct 24, 2018 | Alzheimer's Disease
CTAD poster 2018 The effect of crenezumab on beta-amyloid toxicity–induced synapse loss, neurofibrillary tangles and cell death in human neurons in vitroOct 24, 2018 | Alzheimer's Disease
Crenezumab is a monoclonal anti-Aβ immunoglobulin G4 (IgG4) antibody currently in development for the treatment of AD. Crenezumab binds to monomeric and aggregated forms of Aβ in vitro, with high affinity for Aβ oligomers, the form of Aβ hypothesized to mediate neurotoxicity in AD. Here we present the results of a preclinical study investigating the ability of crenezumab to protect human neurons from beta-amyloid-related toxicity in vitro, using the human iPSC neuronal model.
Oct 27, 2018 | Alzheimer's Disease CTAD 2018
CTAD oral 2018 Concordance of florbetapir (18F) PET and Elecsys® β-Amyloid(1-42) CSF immunoassay in the CREAD (BN29552) study of crenezumab in prodromal-to-mild AD
Oct 26, 2018 | Alzheimer's Disease CTAD 2018
CTAD oral 2018 Twenty-four–month amyloid PET results of the gantenerumab high-dose SCarlet and Marguerite RoAD open-label extension studies